Potent rewarding and reinforcing effects of the synthetic cathinone 3,4-methylenedioxypyrovalerone (MDPV). 2014

Lucas R Watterson, and Peter R Kufahl, and Natali E Nemirovsky, and Kaveish Sewalia, and Megan Grabenauer, and Brian F Thomas, and Julie A Marusich, and Scott Wegner, and M Foster Olive
Department of Psychology, Arizona State University, Tempe, AZ, USA.

Reports of abuse and toxic effects of synthetic cathinones, frequently sold as 'bath salts' or 'legal highs', have increased dramatically in recent years. One of the most widely used synthetic cathinones is 3,4-methylenedioxypyrovalerone (MDPV). The current study evaluated the abuse potential of MDPV by assessing its ability to support intravenous self-administration and to lower thresholds for intracranial self-stimulation (ICSS) in rats. In the first experiment, the rats were trained to intravenously self-administer MDPV in daily 2-hour sessions for 10 days at doses of 0.05, 0.1 or 0.2 mg/kg per infusion. The rats were then allowed to self-administer MDPV under a progressive ratio (PR) schedule of reinforcement. Next, the rats self-administered MDPV for an additional 10 days under short access (ShA; 2 hours/day) or long access (LgA; 6 hours/day) conditions to assess escalation of intake. A separate group of rats underwent the same procedures, with the exception of self-administering methamphetamine (0.05 mg/kg per infusion) instead of MDPV. In the second experiment, the effects of MDPV on ICSS thresholds following acute administration (0.1, 0.5, 1 and 2 mg/kg, i.p.) were assessed. MDPV maintained self-administration across all doses tested. A positive relationship between MDPV dose and breakpoints for reinforcement under PR conditions was observed. LgA conditions led to escalation of drug intake at 0.1 and 0.2 mg/kg doses, and rats self-administering methamphetamine showed similar patterns of escalation. Finally, MDPV significantly lowered ICSS thresholds at all doses tested. Together, these findings indicate that MDPV has reinforcing properties and activates brain reward circuitry, suggesting a potential for abuse and addiction in humans.

UI MeSH Term Description Entries
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D008297 Male Males
D008694 Methamphetamine A central nervous system stimulant and sympathomimetic with actions and uses similar to DEXTROAMPHETAMINE. The smokable form is a drug of abuse and is referred to as crank, crystal, crystal meth, ice, and speed. Deoxyephedrine,Desoxyephedrine,Desoxyn,Madrine,Metamfetamine,Methamphetamine Hydrochloride,Methylamphetamine,N-Methylamphetamine,Hydrochloride, Methamphetamine,N Methylamphetamine
D011759 Pyrrolidines Compounds also known as tetrahydropyridines with general molecular formula (CH2)4NH. Tetrahydropyridine,Tetrahydropyridines
D012054 Reinforcement, Psychology The strengthening of a conditioned response. Negative Reinforcement,Positive Reinforcement,Psychological Reinforcement,Reinforcement (Psychology),Negative Reinforcements,Positive Reinforcements,Psychological Reinforcements,Psychology Reinforcement,Psychology Reinforcements,Reinforcement, Negative,Reinforcement, Positive,Reinforcement, Psychological,Reinforcements (Psychology),Reinforcements, Negative,Reinforcements, Positive,Reinforcements, Psychological,Reinforcements, Psychology
D012055 Reinforcement Schedule A schedule prescribing when the subject is to be reinforced or rewarded in terms of temporal interval in psychological experiments. The schedule may be continuous or intermittent. Reinforcement Schedules,Schedule, Reinforcement,Schedules, Reinforcement
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004558 Electric Stimulation Use of electric potential or currents to elicit biological responses. Stimulation, Electric,Electrical Stimulation,Electric Stimulations,Electrical Stimulations,Stimulation, Electrical,Stimulations, Electric,Stimulations, Electrical
D000094982 Synthetic Cathinone A propiophenone derivative chemically related to cathinone, a substance found in the KHAT plant. (3,4)-Methylenedioxypyrovalerone,3,4-Methylenedioxypyrovalerone,MDPV,MDPV Compound,Methylenedioxypyrovalerone,Psychoactive Bath Salts,Synthetic Cathinones,((R,S)-MDPV)),Bath Salts, Psychoactive,Cathinones, Synthetic,Salts, Psychoactive Bath
D000697 Central Nervous System Stimulants A loosely defined group of drugs that tend to increase behavioral alertness, agitation, or excitation. They work by a variety of mechanisms, but usually not by direct excitation of neurons. The many drugs that have such actions as side effects to their main therapeutic use are not included here. Analeptic,Analeptic Agent,Analeptic Drug,Analeptics,CNS Stimulant,CNS Stimulants,Central Nervous System Stimulant,Central Stimulant,Analeptic Agents,Analeptic Drugs,Central Stimulants,Agent, Analeptic,Agents, Analeptic,Drug, Analeptic,Drugs, Analeptic,Stimulant, CNS,Stimulant, Central,Stimulants, CNS,Stimulants, Central

Related Publications

Lucas R Watterson, and Peter R Kufahl, and Natali E Nemirovsky, and Kaveish Sewalia, and Megan Grabenauer, and Brian F Thomas, and Julie A Marusich, and Scott Wegner, and M Foster Olive
May 2018, Neuropharmacology,
Lucas R Watterson, and Peter R Kufahl, and Natali E Nemirovsky, and Kaveish Sewalia, and Megan Grabenauer, and Brian F Thomas, and Julie A Marusich, and Scott Wegner, and M Foster Olive
January 2018, Addiction biology,
Lucas R Watterson, and Peter R Kufahl, and Natali E Nemirovsky, and Kaveish Sewalia, and Megan Grabenauer, and Brian F Thomas, and Julie A Marusich, and Scott Wegner, and M Foster Olive
August 2021, Behavioural pharmacology,
Lucas R Watterson, and Peter R Kufahl, and Natali E Nemirovsky, and Kaveish Sewalia, and Megan Grabenauer, and Brian F Thomas, and Julie A Marusich, and Scott Wegner, and M Foster Olive
June 2020, Behavioural pharmacology,
Lucas R Watterson, and Peter R Kufahl, and Natali E Nemirovsky, and Kaveish Sewalia, and Megan Grabenauer, and Brian F Thomas, and Julie A Marusich, and Scott Wegner, and M Foster Olive
November 2016, Journal of clinical pharmacology,
Lucas R Watterson, and Peter R Kufahl, and Natali E Nemirovsky, and Kaveish Sewalia, and Megan Grabenauer, and Brian F Thomas, and Julie A Marusich, and Scott Wegner, and M Foster Olive
December 2013, ACS chemical neuroscience,
Lucas R Watterson, and Peter R Kufahl, and Natali E Nemirovsky, and Kaveish Sewalia, and Megan Grabenauer, and Brian F Thomas, and Julie A Marusich, and Scott Wegner, and M Foster Olive
May 2016, Psychopharmacology,
Lucas R Watterson, and Peter R Kufahl, and Natali E Nemirovsky, and Kaveish Sewalia, and Megan Grabenauer, and Brian F Thomas, and Julie A Marusich, and Scott Wegner, and M Foster Olive
March 2022, Drug and alcohol dependence,
Lucas R Watterson, and Peter R Kufahl, and Natali E Nemirovsky, and Kaveish Sewalia, and Megan Grabenauer, and Brian F Thomas, and Julie A Marusich, and Scott Wegner, and M Foster Olive
December 2012, Journal of addiction research & therapy,
Lucas R Watterson, and Peter R Kufahl, and Natali E Nemirovsky, and Kaveish Sewalia, and Megan Grabenauer, and Brian F Thomas, and Julie A Marusich, and Scott Wegner, and M Foster Olive
March 2018, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,
Copied contents to your clipboard!